4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $25.00 by Analysts at Chardan Capital

4D Molecular Therapeutics (NASDAQ:FDMT) had its price target decreased by Chardan Capital from $28.00 to $25.00 in a research report released on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the stock.

Several other brokerages have also issued reports on FDMT. Bank of America lowered their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, March 10th. The Goldman Sachs Group lowered their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, March 3rd. Leerink Partners lowered their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Finally, BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Stock Down 4.9%

NASDAQ FDMT opened at $3.08 on Friday. 4D Molecular Therapeutics has a twelve month low of $2.24 and a twelve month high of $28.93. The company has a market cap of $142.68 million, a price-to-earnings ratio of -1.08 and a beta of 2.87. The business’s fifty day moving average is $3.38 and its 200 day moving average is $5.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.02). On average, research analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Privium Fund Management B.V. raised its position in shares of 4D Molecular Therapeutics by 8.3% in the 1st quarter. Privium Fund Management B.V. now owns 131,000 shares of the company’s stock worth $423,000 after acquiring an additional 10,000 shares in the last quarter. Federated Hermes Inc. increased its position in 4D Molecular Therapeutics by 33,131.8% in the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock valued at $4,038,000 after buying an additional 1,246,419 shares in the last quarter. Proficio Capital Partners LLC increased its position in 4D Molecular Therapeutics by 26.0% in the 1st quarter. Proficio Capital Partners LLC now owns 25,195 shares of the company’s stock valued at $75,000 after buying an additional 5,195 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in 4D Molecular Therapeutics in the 1st quarter valued at about $41,000. Finally, Peapod Lane Capital LLC increased its position in 4D Molecular Therapeutics by 35.3% in the 1st quarter. Peapod Lane Capital LLC now owns 195,853 shares of the company’s stock valued at $633,000 after buying an additional 51,110 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.